Thursday - May 8, 2025
Toronto, Ontario – The Newswire – November 3, 2023 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSXV:VPT) (OTC:VPTDF) is pleased to announce the results of its annual general and special meeting of shareholders held on November 1, 2023, in Toronto (the "Meeting"). Shareholders voted in favour of each of the matters considered at the Meeting, including electing each of Dr. George Adams, Robert Hodgkinson, Hugh MacNaught, Fiona Fitzgerald, Randy AuCoin, and Dr. Alvira Macanovic as directors of the Company to hold office for the ensuing year, appointing MNP LLP as the Company's auditors for the ensuing year, authorizing the board of directors to set their remuneration, and re-approving the Company’s stock option plan, all as described in the Company’s Information Circular dated October 2, 2023.
The CEO slide presentation and transcript are available on the Ventripoint website at: https://www.ventripoint.com/annual-meeting.
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.
For further information, please contact:
Jonathan Robinson
416-669-1001
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Last Trade: | C$0.14 |
Daily Change: | -0.005 -3.57 |
Daily Volume: | 155,815 |
Market Cap: | C$21.560M |
March 24, 2025 March 21, 2025 February 27, 2025 February 10, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load